title: Immunohistochemical localization of the proteoglycans decorin, biglycan and versican and transforming growth factor-beta in human post-burn hypertrophic and mature scars.
abstract: The distributions of the small proteoglycans, decorin and biglycan and the large proteoglycan, versican, in normal skin and post-burn hypertrophic and mature scars, were compared using monoclonal and polyclonal antibodies to the core proteins. Biglycan and versican were virtually undetectable in normal dermis but readily seen in hypertrophic scars. Staining for decorin was strong throughout the dermis in normal skin but restricted to the deep dermis and a narrow zone under the epidermis in hypertrophic scar--areas which did not stain for versican. Decorin was absent or reduced in the nodules in these specimens. In mature post-burn scars, staining for all three proteoglycans demonstrated an intensity that was intermediate between that in normal dermis and that in the nodules of the hypertrophic scars. Transforming growth factor-beta was present in the nodules of hypertrophic scars but the deep dermis of these specimens stained most intensely for this cytokine which was also found in the dermis of mature scars but was not detectable in normal dermis. The apparent co-distribution of decorin and transforming growth factor-beta suggests that this proteoglycan may play an active role in the resolution of the scars. Changes in proteoglycan type and distribution could possibly account, at least in part, for the derangement of collagen and the altered physical properties of hypertrophic scar tissue.
authors.affiliation: Department of Oral Biology, University of Alberta, Edmonton, Canada.
authors.forename: P G
authors.initials: PG
authors.lastname: Scott
authors.forename: C M
authors.initials: CM
authors.lastname: Dodd
authors.forename: E E
authors.initials: EE
authors.lastname: Tredget
authors.forename: A
authors.initials: A
authors.lastname: Ghahary
authors.forename: F
authors.initials: F
authors.lastname: Rahemtulla
mesh_terms: D000328:Adult; D000595:Amino Acid Sequence; D000918:Antibody Specificity / Q000276:immunology; D058578:Biglycan; D002056:Burns / Q000150:complications / Q000276:immunology*; D016022:Case-Control Studies; D002648:Child; D011508:Chondroitin Sulfate Proteoglycans / Q000032:analysis; D002921:Cicatrix / Q000150:complications / Q000276:immunology*; D017439:Cicatrix, Hypertrophic / Q000150:complications / Q000276:immunology; D058575:Decorin; D000939:Epitopes / Q000276:immunology; D016326:Extracellular Matrix Proteins; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D037181:Lectins, C-Type; D008297:Male; D008969:Molecular Sequence Data; D011509:Proteoglycans / Q000032:analysis*; D016212:Transforming Growth Factor beta / Q000032:analysis*; D053675:Versicans
chemical_list: C546884:BGN protein, human; D058578:Biglycan; D011508:Chondroitin Sulfate Proteoglycans; C546878:DCN protein, human; D058575:Decorin; D000939:Epitopes; D016326:Extracellular Matrix Proteins; D037181:Lectins, C-Type; D011509:Proteoglycans; D016212:Transforming Growth Factor beta; C508322:VCAN protein, human; D053675:Versicans